Q1 EPS Forecast for Inovio Pharmaceuticals Raised by Analyst

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - Analysts at HC Wainwright boosted their Q1 2025 EPS estimates for Inovio Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.75) per share for the quarter, up from their previous estimate of ($0.78). HC Wainwright has a "Neutral" rating and a $3.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals' current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals' Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($2.12) EPS.

A number of other analysts also recently issued reports on INO. StockNews.com raised Inovio Pharmaceuticals to a "sell" rating in a research report on Friday. Royal Bank of Canada decreased their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating for the company in a report on Wednesday, March 19th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $12.20.

Remove Ads

Inovio Pharmaceuticals Trading Down 3.7 %

Shares of INO stock traded down $0.07 during trading hours on Friday, hitting $1.81. 1,027,520 shares of the company were exchanged, compared to its average volume of 552,282. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75. The firm has a fifty day simple moving average of $2.04 and a 200 day simple moving average of $3.64. The stock has a market capitalization of $47.24 million, a price-to-earnings ratio of -0.45 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.18. The company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.03 million.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Alpine Global Management LLC purchased a new position in Inovio Pharmaceuticals during the 4th quarter valued at about $31,000. Stonepine Capital Management LLC bought a new position in shares of Inovio Pharmaceuticals in the fourth quarter valued at approximately $1,922,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Inovio Pharmaceuticals during the fourth quarter valued at approximately $412,000. Graham Capital Management L.P. bought a new stake in Inovio Pharmaceuticals during the 4th quarter worth approximately $114,000. Finally, Deutsche Bank AG lifted its stake in Inovio Pharmaceuticals by 524.6% in the 4th quarter. Deutsche Bank AG now owns 89,864 shares of the biopharmaceutical company's stock worth $164,000 after purchasing an additional 75,477 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.